Ekdv-691

| Phase | Indication | Design | Estimated Enrollment | |-------|------------|--------|----------------------| | | IPF (monotherapy vs. standard‑of‑care) | Randomized, double‑blind, 48‑week; three arms (placebo, EKDV‑691 60 mg, EKDV‑691 60 mg + pirfenidone) | 300 | | Phase IIb/III | Systemic sclerosis‑associated interstitial lung disease (SSc‑ILD) | Adaptive seamless design; primary endpoint: change in FVC at week 52 | 250 | | Phase II | Desmoplastic pancreatic cancer (in combination with nab‑paclitaxel) | Open‑label, biomarker‑enriched (high DDR1 expression) | 80 | | Phase I/II | Chronic kidney disease (CKD) with tubulointerstitial fibrosis | Exploratory safety & PD | 60 |